Stay updated on KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Sign up to get notified when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.

Latest updates to the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page
- Check3 days agoChange DetectedThe sponsor field was updated from 'Karuna Therapeutics' to 'Karuna Therapeutics, Inc., a Bristol Myers Squibb company' to reflect the full corporate affiliation.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision: v3.5.0 added and Revision: v3.4.3 removed in the Record History.SummaryDifference0.1%

- Check24 days agoChange DetectedA new revision entry v3.4.3 was added and the v3.4.2 entry was removed from the page history.SummaryDifference0.1%

- Check53 days agoChange DetectedAdded Revision: v3.4.2 to the history, marking a new release in the study record's version list. Removed the older funding-status notice and Revision: v3.4.1 from the history view.SummaryDifference0.6%

- Check60 days agoChange DetectedAdded a government funding lapse notice and a new page revision tag (Revision: v3.4.1); the previous revision tag (v3.4.0) was removed.SummaryDifference0.6%

- Check67 days agoChange DetectedThe history page now includes a 'Show glossary' option and color-coded highlights for additions and deletions, with a new Revision: v3.4.0.SummaryDifference0.8%

Stay in the know with updates to KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.